Literature DB >> 8157281

Reduction of spontaneous autoimmune diabetes in diabetes-prone BB rats with the novel immunosuppressant fusidic acid. Effect on T-cell proliferation and production of interferon-gamma.

F Nicoletti1, R Di Marco, S Morrone, P Zaccone, D Lembo, S Grasso, A Santoni, P L Meroni, K Bendtzen.   

Abstract

Diabetes-prone (DP) BB rats spontaneously develop a hyperglycaemic condition which closely resembles human insulin-dependent diabetes mellitus (IDDM), both in terms of clinical and histological features. The incidence of IDDM was significantly reduced when these animals were treated with 2 or 4 mg fusidic acid (FA)/day i.m. from day 30 to day 120 of age. In addition, the mean insulitis score was significantly diminished in the animals treated with FA compared to both vehicle-treated and untreated controls. Finally, 2 mg/day of FA i.m. prevented cell proliferation and interferon-gamma secretion from peripheral blood mononuclear cells upon ex vivo stimulation with concanavalin A. The capacity of FA to substantially reduce the incidence of autoimmune diabetes in a well-known animal model of human IDDM supports previous observations regarding the immunosuppressive properties of FA and its potential use in the treatment of human autoimmune diabetes.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8157281      PMCID: PMC1422331     

Source DB:  PubMed          Journal:  Immunology        ISSN: 0019-2805            Impact factor:   7.397


  34 in total

1.  Sodium fusidate and increased remission rate of insulin-dependent diabetes mellitus.

Authors:  F Nicoletti; P L Meroni; M Lunetta; R Vigo; T Palermo; D Papalia; W Barcellini; M Di Mauro; M Caruso-Nicoletti; L Mughini
Journal:  Lancet       Date:  1991-05-25       Impact factor: 79.321

2.  Treatment of chronic endogenous uveitis with fusidic acid.

Authors:  K Bendtzen; N Vesti-Nielsen; J Petersen; V Andersen; G Bendixen
Journal:  Lancet       Date:  1991-03-02       Impact factor: 79.321

Review 3.  FK 506: an immunosuppressant for the 1990s?

Authors:  A M Macleod; A W Thomson
Journal:  Lancet       Date:  1991-01-05       Impact factor: 79.321

4.  Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis.

Authors:  P Tugwell; C Bombardier; M Gent; K J Bennett; W G Bensen; S Carette; A Chalmers; J M Esdaile; A V Klinkhoff; G R Kraag
Journal:  Lancet       Date:  1990-05-05       Impact factor: 79.321

Review 5.  A new view of the beta cell as an antigen-presenting cell and immunogenic target.

Authors:  I L Campbell; L C Harrison
Journal:  J Autoimmun       Date:  1990-04       Impact factor: 7.094

6.  Prevention of diabetes in BB/Wor rats treated with monoclonal antibodies to interferon-gamma.

Authors:  F Nicoletti; P L Meroni; S Landolfo; M Gariglio; S Guzzardi; W Barcellini; M Lunetta; L Mughini; C Zanussi
Journal:  Lancet       Date:  1990-08-04       Impact factor: 79.321

7.  Cyclosporin in idiopathic steroid-resistant membranous glomerulonephritis.

Authors:  G Rostoker; L Toro; A Ben Maadi; J Ryckelynk; T Sadreux; J Rivalan; D Chevet; C Janin; P Lang; B Weil
Journal:  Lancet       Date:  1989-10-21       Impact factor: 79.321

8.  Treatment of aplastic anemia with antilymphocyte globulin and methylprednisolone with or without cyclosporine. The German Aplastic Anemia Study Group.

Authors:  N Frickhofen; J P Kaltwasser; H Schrezenmeier; A Raghavachar; H G Vogt; F Herrmann; M Freund; P Meusers; A Salama; H Heimpel
Journal:  N Engl J Med       Date:  1991-05-09       Impact factor: 91.245

9.  Essential role for interferon-gamma and interleukin-6 in autoimmune insulin-dependent diabetes in NOD/Wehi mice.

Authors:  I L Campbell; T W Kay; L Oxbrow; L C Harrison
Journal:  J Clin Invest       Date:  1991-02       Impact factor: 14.808

10.  Preliminary report: cyclosporin in treatment of severe active ulcerative colitis.

Authors:  S Lichtiger; D H Present
Journal:  Lancet       Date:  1990-07-07       Impact factor: 79.321

View more
  5 in total

1.  Lack of effect of intermittently administered sodium fusidate in patients with newly diagnosed type 1 diabetes mellitus: the FUSIDM trial.

Authors:  I Conget; E Aguilera; S Pellitero; S Näf; K Bendtzen; R Casamitjana; R Gomis; F Nicoletti
Journal:  Diabetologia       Date:  2005-07-02       Impact factor: 10.122

2.  Improved survival and antagonistic effect of sodium fusidate on tumor necrosis factor alpha in a neonatal mouse model of endotoxin shock.

Authors:  F Genovese; G Mancuso; M Cuzzola; V Cusumano; F Nicoletti; K Bendtzen; G Teti
Journal:  Antimicrob Agents Chemother       Date:  1996-07       Impact factor: 5.191

3.  Effects of sodium fusidate in animal models of insulin-dependent diabetes mellitus and septic shock.

Authors:  F Nicoletti; P Zaccone; R Di Marco; G Magro; S Grasso; S Morrone; A Santoni; G Tempera; P L Meroni; K Bendtzen
Journal:  Immunology       Date:  1995-08       Impact factor: 7.397

4.  Type-specific human papillomavirus detection in cervical smears in Romania.

Authors:  Gabriela Anton; Gheorghe Peltecu; Demetra Socolov; Florinel Cornitescu; Coralia Bleotu; Zorela Sgarbura; Sergiu Teleman; Dominic Iliescu; Anca Botezatu; Cristina D Goia; Irina Huica; Ana-Cristina Anton
Journal:  APMIS       Date:  2010-10-25       Impact factor: 3.205

5.  Diol-ginsenosides from Korean Red Ginseng delay the development of type 1 diabetes in diabetes-prone biobreeding rats.

Authors:  Chung Ju; Sang-Min Jeon; Hee-Sook Jun; Chang-Kiu Moon
Journal:  J Ginseng Res       Date:  2019-06-12       Impact factor: 6.060

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.